Summary & Overview
CPT 87502: Influenza Virus Detection by Multiplex Nucleic Acid Technique
CPT code 87502 represents a laboratory procedure for detecting influenza virus types and subtypes using advanced nucleic acid techniques. This test is critical for identifying influenza infections, enabling clinicians to differentiate between various strains and subtypes, which is vital for patient management and epidemiological tracking. The code is widely used in clinical laboratories across the United States, reflecting its importance in both routine and outbreak settings.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, provide coverage for this laboratory service. The publication offers insights into payer coverage, relevant policy updates, and clinical context for the use of 87502. Readers will gain an understanding of how this code fits within the broader landscape of infectious disease diagnostics, including its relationship to other influenza testing codes and associated clinical diagnoses. The summary also highlights common billing modifiers and taxonomies relevant to laboratory and pathology services, ensuring stakeholders are informed about coding practices and payer requirements.
This article serves as a comprehensive resource for healthcare professionals, laboratory administrators, and policy analysts seeking to stay current on laboratory coding, payer coverage, and clinical benchmarks for influenza virus detection.
CPT Code Overview
CPT code 87502 is used for the detection of infectious agents by nucleic acid, specifically targeting the influenza virus. This procedure utilizes multiplex reverse transcription and amplified probe techniques to identify each type or subtype of the influenza virus. The service is classified as a laboratory test and is typically performed in a laboratory setting (Place of Service 81). This code is essential for accurate and timely diagnosis of influenza, supporting clinical decision-making and public health surveillance.
Clinical & Coding Specifications
Clinical Context
A patient presents to their primary care provider or urgent care with symptoms suggestive of influenza, such as fever, cough, sore throat, and respiratory distress. The provider orders a laboratory test to detect the presence and subtype of influenza virus using multiplex reverse transcription and amplified probe technique. The specimen, typically a nasopharyngeal swab, is sent to a clinical laboratory (Place of Service 81) for analysis. The laboratory performs the procedure described by CPT code 87502 to identify the specific type or subtype of influenza virus, aiding in diagnosis and guiding treatment decisions.
Coding Specifications
Common Modifiers:
-
Modifier
59: Distinct Procedural Service. Used when the procedure is performed separately from other services, indicating it is not part of a bundled service. -
Modifier
91: Repeat Clinical Diagnostic Laboratory Test. Used when the same laboratory test is performed more than once on the same day for the same patient, typically to monitor disease progression or response to treatment.
Associated Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
291U00000X | Clinical Medical Laboratory |
207ZP0102X | Pathology |
207Q00000X | Family Medicine Physician |
These taxonomies represent the clinical laboratory performing the test, pathologists overseeing laboratory operations, and family medicine physicians ordering the test.
Related Diagnoses
-
J10.1: Influenza with other respiratory manifestations, seasonal influenza virus identified- Relevant for patients with confirmed seasonal influenza and additional respiratory symptoms.
-
J11.1: Influenza with other respiratory manifestations, virus not identified- Used when influenza is suspected with respiratory symptoms, but the virus is not specifically identified.
-
J09.X2: Influenza due to identified novel influenza A virus with other respiratory manifestations- Applies to cases involving novel influenza A strains with respiratory symptoms.
-
J10.0: Influenza with pneumonia, seasonal influenza virus identified- Indicates influenza infection with pneumonia, confirmed as seasonal influenza.
-
J11.0: Influenza with pneumonia, virus not identified- Used when pneumonia is present and influenza is suspected, but the virus is not specifically identified.
Each diagnosis code is clinically relevant for patients presenting with symptoms that warrant laboratory testing for influenza virus detection using CPT code 87502.
Related CPT Codes
| CPT Code | Description | Clinical Relationship |
|---|---|---|
87400 | Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple-step method; influenza virus, direct or indirect immunofluorescent antibody staining | Alternative method for influenza detection; may be used when nucleic acid testing is not available. |
87804 | Infectious agent antigen detection by immunoassay with direct optical observation; influenza | Rapid antigen test for influenza; often used in point-of-care settings as an initial screening tool. |
87631 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, multiplex reverse transcription and amplified probe technique, multiple types or subtypes, 3-5 targets | Multiplex test for multiple respiratory viruses; may be used when broader viral testing is needed. |
87632 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, multiplex reverse transcription and amplified probe technique, multiple types or subtypes, 6-11 targets | Expanded multiplex test for multiple respiratory viruses; used when comprehensive viral screening is required. |
Codes 87400 and 87804 are commonly used as alternatives or adjuncts to 87502 for influenza detection. Codes 87631 and 87632 are used when testing for multiple respiratory viruses in addition to influenza.
National Reimbursement Benchmarks
For CPT code 87502, national mean rates among commercial payers (BUCA) are $86.37, which is notably higher than typical Medicare rates, though Medicare data is not available in the input. Among individual commercial payers, Aetna and Cigna have the highest mean rates at $100.78 and $99.12, respectively, while UnitedHealth Group and Blue Cross Blue Shield are lower at $77.89 and $75.38.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies across payers. UnitedHealth Group shows the widest spread ($46.00), indicating significant variability in contracted rates. Blue Cross Blue Shield has a tighter range ($43.00), while Aetna ($36.50) and BUCA ($38.08) are more moderate. Cigna exhibits the largest dispersion ($69.75), suggesting the broadest variability in rates among the major payers.
The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.